ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Calcinosis and juvenile dermatomyositis"

  • Abstract Number: 88 • 2017 Pediatric Rheumatology Symposium

    Clinical Features and Frequency of Biologic use in Patients with Juvenile Dermatomyositis-associated Calcinosis

    Amir Orandi1, Vikas Dharnidharka2, Noor Al-Hammadi3 and Kevin Baszis1, 1Pediatric Rheumatology, Washington University in St. Louis School of Medicine, Saint Louis, MO, 2Pediatric Nephrology, Washington University in St. Louis School of Medicine, Saint Louis, MO, 3Division of Biostatistics, Washington University in St. Louis School of Medicine, St Louis, MO

    Background/Purpose: Calcinosis develops in an estimated 40% of patients with Juvenile Dermatomyositis (JDM). Conflicting studies have not definitively identified actionable risk factors or demonstrated that…
  • Abstract Number: 89 • 2017 Pediatric Rheumatology Symposium

    Abatacept as Adjunct Therapy for the Calcinosis of Juvenile Dermatomyositis: A Single-Center Experience

    Marietta DeGuzman1, Saimun Singla1, Melissa Mizesko2 and Anna Carmela Sagcal-Gironella3, 1Pediatric Immunology, Allergy and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, 2Division of Rheumatology, Driscoll Children's Hospital, Corpus Christi, TX, 3Pediatric Immunology, Allergy, and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX

    Background/Purpose: Juvenile dermatomyositis (JDMS) is an autoimmune inflammatory myopathy which primarily manifests with skin, muscle, and blood vessel involvement. Dystrophic calcification or calcinosis has been…
  • Abstract Number: 2065 • 2013 ACR/ARHP Annual Meeting

    The Prevalence and Clinical Usefulness Of Anti-NXP-2 Autoantibodies In Chinese Patients With Idiopathic Inflammatory Myopathies

    Xin Lu1, Guochun Wang2, Qinglin Peng3, Kai Yuan4 and Hanbo Yang5, 1Department of Rheumatology, China-Japan Friendship Hospital, Beijing, China, Beijing, China, 2Department of Rheumatology, China-Japan Friendship Hospital, Beijing, China, 3Department of Rheumatology,, China-Japan Friendship Hospital, Beijing, China, 4Department of Rheumatology and Immunology, China-Japan Friendship Hospital, Beijing, China, 5Rheumatology, China-Japan Friendship Hospital, Beijing, China

    Background/Purpose: To determine the sera levels of anti-NXP-2 antibodies and their clinical association in Chinese patients with idiopathic inflammatory myopathies(IIM). Methods: Sera from 198 Chinese…
  • Abstract Number: 301 • 2012 ACR/ARHP Annual Meeting

    Decreased Frequency of Dystrophic Calcifications in Children with Juvenile Dermatomyositis: A 10-Year Study

    Lauren M. Pachman1, Gabrielle A. Morgan2, Megan L. Curran1, Lori J. Ferguson3 and Chiang-Ching Huang4, 1Division of Pediatric Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, 2Cure JM Myositis Center, Ann & Robert H. Lurie Children's Hospital of Chicago Research Center, Chicago, IL, 3Children's Hospital of Chicago Research Center, Cure JM Myositis Center, Chicago, IL, 4Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL

    Background/Purpose: In Juvenile Dermatomyositis (JDM), dystrophic calcifications, associated with increased morbidity and mortality, have been reported for 20-30% of patients. There are few laboratory indicators…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology